Good question @Taureanbull Here is my laymans take. Each of those 100+ indications is the result of a different genetic mutation all of which ending up producing a similar range of symptoms. Those symptoms eg hand wringing, poor communication, gastrointestinal problems seem to be improved across the board by our molecules. So it might be difficult for a regulator to sign off on approval for use in all or many indications just because it is efficacious in 4 or 6.
If that was the case a Doctor with a patient with say a Rett's adjacent condition would be busting to prescribe 2591 off label. But how do you get reimbursed for a $300k drug that's not approved specifically for your patient's syndrome?
Maybe a BP with a huge trial budget could design a blockbuster trial for a spectrum of syndromes and symptoms and get to a HUGE market that way. Others here will know bettter than me so feel free to jump in.
- Forums
- ASX - By Stock
- NEU
- Moonsoon Briefing Thurs 20 April
Moonsoon Briefing Thurs 20 April, page-65
-
- There are more pages in this discussion • 30 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add NEU (ASX) to my watchlist
(20min delay)
|
|||||
Last
$13.56 |
Change
-0.360(2.59%) |
Mkt cap ! $1.733B |
Open | High | Low | Value | Volume |
$13.94 | $13.96 | $13.50 | $6.421M | 470.4K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
2 | 1643 | $13.54 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$13.61 | 3100 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
2 | 1643 | 13.540 |
2 | 2409 | 13.530 |
1 | 3769 | 13.520 |
1 | 3723 | 13.510 |
7 | 9971 | 13.500 |
Price($) | Vol. | No. |
---|---|---|
13.610 | 3100 | 1 |
13.640 | 2409 | 1 |
13.650 | 1643 | 4 |
13.670 | 2409 | 1 |
13.690 | 2409 | 1 |
Last trade - 16.10pm 06/09/2024 (20 minute delay) ? |
Featured News
NEU (ASX) Chart |